Results 201 to 210 of about 4,949,451 (244)

Iron Chelation in Thalassemia Major

Clinical Therapeutics, 2015
Iron chelation has improved survival and quality of life of patients with thalassemia major. there are currently 3 commercially available iron-chelating drugs with different pharmacokinetic and pharmacodynamic activity. The choice of adequate chelation treatment should be tailored to patient needs and based on up-to-date scientific evidence.A review of
BORGNA, Caterina, Marsella, M.
openaire   +2 more sources

Auditory Involvement in Thalassemia Major

Acta Haematologica, 2009
The auditory function of 75 children affected by homozygous β°-thalassemia, managed with a low transfusion scheme and treated irregularly with low doses of desferrioxamine, and of 75 controls were examined. In 12 patients a mild bilateral conductive hearing impairment due to bony hypertrophy and/or adenoid hypertrophy was found.
S, De Virgiliis, F, Argiolu, G, Sanna, G, Cornacchia, P, Cossu, A, Cao, V, Mallardi, P, Puxeddu   +7 more
openaire   +2 more sources

Home treatment in thalassemia major.

Acta paediatrica Belgica, 1979
info:eu-repo/semantics ...
Alexander, Marc, Luyckx, W., Fonfu, P.
openaire   +2 more sources

Neutropenia in Patients with Thalassemia Major.

Blood, 2004
Abstract Monitoring of the neutrophil count has become an important issue in the management of thalassemia patients after the introduction of the new oral chelator deferiprone, as this chelator has been associated with agranulocytosis and milder neutropenias.
GALANELLO, RENZO, ORIGA, RAFFAELLA
openaire   +2 more sources

Update on Survival in Thalassemia Major

Hemoglobin, 2009
Long-term follow-up of cohorts of patients treated in high-income countries has shown a progressive improvement in life expectancy. Myocardial toxicity from iron overload has been the major cause of mortality; however, there has been a substantial decline in cardiac deaths in recent years, related to switching high-risk patients from subcutaneous ...
openaire   +2 more sources

Growth and Puberty in Thalassemia Major

Journal of Pediatric Endocrinology and Metabolism, 1995
Growth and sexual development were evaluated in 54 (29 female, 25 male) patients with beta-thalassemia major aged 2.7-21.3 years (mean 10.4 yr). Mean pretransfusion hemoglobin concentration was 7.8 +/- 0.7 mg/dl. All patients except 6 were on desferrioxamine. Age of starting of therapy was 6.8 +/- 3.9 years.
N, Saka, M, Sükür, R, Bundak, S, Anak, O, Neyzi, G, Gedikoğlu   +5 more
openaire   +2 more sources

Hepcidin and β-thalassemia major

Blood, 2013
In this issue of Blood, Pasricha et al evaluated serum hepcidin and its putative pathological suppressor growth differentiation factor-15 (GDF-15) in patients with β-thalassemia major before and after transfusion, in the context of erythropoietic activity and iron loading.
openaire   +2 more sources

Hepatitis in children with thalassemia major

1992
Since thalassemia major patients are transfusion dependent, they are at a particularly high risk of contracting post-transfusion hepatitis. In this study, 36 transfusion-dependent children were followed up for evidence of viral hepatitis. Of 23 with increased ALT levels, 17 were anti-CMV and 12 were anti-HCV positive, 9 were positive for both CMV and ...
G, Nigro, G, Taliani, U, Bartmann, R, Vitolo, T, Perrone, S, Mattia, P, Pisano, A, Petruccelli, S, Maiozzi, M, Midulla   +9 more
openaire   +2 more sources

Fertility and Pregnancy in Thalassemia Major

Annals of the New York Academy of Sciences, 2005
Abstract: Over the last 15 years, 22 women with thalassemia major have completed 29 pregnancies at the Royal Hospital in London. The major pre‐pregnancy issues, medications, and pregnancy care are reviewed. Experience suggests that, with proper care and guidance, pregnancies among women with thalassemia major are practical and can have successful ...
openaire   +2 more sources

Growth and puberty in thalassemia major.

Journal of pediatric endocrinology & metabolism : JPEM, 2003
Present transfusional regimen protocols increase the life expectancy of patients with beta-thalassemia major, but cause a progressive iron overload that can be prevented or limited only by appropriate iron chelation. Siderosis is responsible for the clinical complications of the disease. Short stature and hypogonadism are extremely frequent in patients
RAIOLA G, GALATI MC, DE SANCTIS V, CARUSO, Manuela Clementina Maria, PINTOR C, DE SIMONE M, ARCURI VM, ANASTASI S.   +7 more
openaire   +2 more sources